Great Point Partners LLC Alpine Immune Sciences, Inc. Transaction History

Great Point Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.75 - $41.6 $45.7 Million - $107 Million	-2,574,934 Reduced 69.53%	1,128,499 $44.7 Million
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $5.34 Million - $12.6 Million	624,800 Added 20.29%	3,703,433 $70.6 Million
Q3 2023 Nov 14, 2023	SELL	$10.13 - $13.98 $2.89 Million - $3.99 Million	-285,055 Reduced 8.47%	3,078,633 $35.3 Million
Q2 2023 Aug 14, 2023	SELL	$6.84 - $11.91 $2.58 Million - $4.49 Million	-377,073 Reduced 10.08%	3,363,688 $34.6 Million
Q1 2023 May 15, 2023	BUY	$7.0 - $8.75 $721,301 - $901,626	103,043 Added 2.83%	3,740,761 $28.9 Million
Q4 2022 Feb 14, 2023	BUY	$5.45 - $7.35 $1.03 Million - $1.39 Million	189,197 Added 5.49%	3,637,718 $26.7 Million
Q3 2022 Nov 14, 2022	BUY	$6.89 - $9.39 $20 Million - $27.3 Million	2,909,702 Added 540.01%	3,448,521 $24.8 Million
Q2 2022 Aug 15, 2022	BUY	$6.71 - $9.52 $3.62 Million - $5.13 Million	538,819 New	538,819 $4.59 Million

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.